Abbott Laboratories 2022 Q2 Form 10-Q Summary
Business Context and Reporting Period
Abbott Laboratories reported unaudited results for the quarter and six months ended June 30, 2022. The company operates through Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices, with sales across the United States and international markets.
Financial Results and Key Metrics
- Second-quarter net sales: $11.257 billion, up 10.1% reported and 14.3% excluding foreign exchange versus $10.223 billion in the prior-year quarter.
- Six-month net sales: $23.152 billion, up 12.0% reported and 15.9% excluding foreign exchange versus $20.679 billion.
- Second-quarter operating earnings: $2.376 billion versus $1.392 billion; operating margin was approximately 21.1% versus 13.6%.
- Six-month operating earnings: $5.288 billion versus $3.501 billion; operating margin was approximately 22.8% versus 16.9%.
- Second-quarter net earnings: $2.018 billion, or $1.14 diluted earnings per share, versus $1.189 billion, or $0.66 per share.
- Six-month net earnings: $4.465 billion, or $2.51 diluted earnings per share, versus $2.982 billion, or $1.66 per share.
- Net margin: Approximately 17.9% in the second quarter and 19.3% for the first six months, compared with approximately 11.6% and 14.4%, respectively, in the prior-year periods.
- Gross margin: 51.7% in the second quarter and 52.8% for the first six months, compared with 46.7% and 49.9% in the prior-year periods.
- Operating cash flow: $4.475 billion for the first six months, down from $4.765 billion, primarily because of increased working-capital investment and higher pension contributions.
- Capital expenditures: $700 million for the first six months versus $810 million.
- Cash and short-term investments: $9.290 billion at June 30, 2022, compared with $10.249 billion at December 31, 2021.
- Debt: $16.760 billion of long-term debt, including the current portion, versus $18.050 billion at year-end 2021. Abbott repaid $750 million of 2.55% notes at maturity in March 2022.
- Liquidity: Working capital was $12.6 billion at June 30, 2022. Abbott reported $5.0 billion of credit lines expiring in 2025 and investment-grade debt ratings of AA- from Standard & Poor’s and A1 from Moody’s.
Segment Performance and Changes Versus Prior Year
- Diagnostics: First-half sales increased 32.3% reported and 35.9% excluding foreign exchange to $9.608 billion. Rapid Diagnostics sales rose 70.4% excluding foreign exchange, primarily from COVID-19 testing demand.
- Medical Devices: First-half sales increased 4.8% reported and 9.4% excluding foreign exchange to $7.322 billion, led by Diabetes Care, Electrophysiology, Structural Heart, and Heart Failure.
- Established Pharmaceutical Products: First-half sales increased 5.3% reported and 11.2% excluding foreign exchange to $2.370 billion.
- Nutritional Products: First-half sales declined 7.2% reported and 4.4% excluding foreign exchange to $3.847 billion, primarily because of the U.S. pediatric formula recall and production stoppage.
- COVID-19 testing: Sales were approximately $2.3 billion in the second quarter and $5.6 billion in the first six months, versus approximately $1.3 billion and $3.5 billion, respectively, in the prior-year periods. Excluding COVID-19 testing sales and foreign exchange, total sales increased 4.1% in the quarter and 5.9% year to date.
- Foreign exchange: A stronger U.S. dollar reduced second-quarter total sales by 4.2% and international sales by 6.5%; for the first six months, the effects were 3.9% and 6.2%, respectively.
- Margin improvement: Gross margin benefited from the absence of $499 million of 2021 COVID-19 diagnostic manufacturing restructuring charges, higher COVID-19 rapid-test volume, productivity initiatives, and foreign exchange effects. Benefits were partly offset by the nutritional recall, inflation, supply-chain costs, and lower COVID-19 sales in certain laboratory diagnostics.
Guidance, Outlook, Risks, and Unusual Items
- Guidance: The filing text does not provide a clear quantitative earnings or revenue guidance update.
- Infant formula recall: Abbott initiated a voluntary recall in February 2022 involving certain infant powder formula products made at its Sturgis, Michigan facility and halted production. U.S. pediatric nutrition sales fell 27.5% in the first six months. A May 2022 FDA consent decree established requirements for resuming operations; partial production restarted July 1, 2022.
- Recall-related charges: The company recorded $42 million in the second quarter and $162 million in the first six months of 2022 related to the voluntary nutritional-product recall.
- COVID-19 exposure: Management stated that the duration and future impact of the pandemic remain uncertain. The significant contribution from COVID-19 testing creates potential volatility as testing demand changes.
- Operational pressures: Management cited inflation, commodities and distribution costs, supply-chain constraints, healthcare staffing challenges, COVID-19 case surges, and China quarantine restrictions.
- Restructuring: The 2021 diagnostic manufacturing restructuring generated $499 million of second-quarter 2021 charges; no comparable charge was recorded in the 2022 quarter. Remaining restructuring accruals totaled $44 million at June 30, 2022.
- Contingencies: Legal and environmental exposures were estimated at approximately $30 million to $45 million, with an accrued balance of approximately $40 million. Management did not expect a material adverse effect from their ultimate resolution.
- Taxes: Abbott stated that gross unrecognized tax benefits could decrease by approximately $90 million to $115 million over the following 12 months as tax matters are resolved.
- Shareholder returns: Abbott paid $1.660 billion of dividends and repurchased $2.312 billion of common shares during the first six months. The quarterly dividend was $0.47 per share, up from $0.45.
Important Facts for Investors to Verify
- Whether U.S. infant-formula production and sales fully recover following the Sturgis facility restart and FDA consent decree.
- The sustainability of COVID-19 testing revenue and the effect of declining or volatile testing demand on Diagnostics growth and margins.
- Underlying growth excluding COVID-19 testing, foreign exchange, and recall-related effects.
- Progress on inventory, receivables, and working-capital normalization, given the $1.030 billion increase in inventories and $939 million use of cash from receivables during the first six months.
- Foreign-exchange sensitivity, supply-chain and inflation impacts, and healthcare procedure-volume recovery.
- Remaining share-repurchase authorization of approximately $3.981 billion and future debt repayment or redemption activity.
- The filing’s stated legal, environmental, tax, and product-liability exposures and any subsequent changes to recorded accruals.